BDBM282933 6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-1H- imidazol-5-yl)imidazo[1,2-b]pyridazine-3-carboxamide::US10287295, Example 138'::US11352360, Example 138'::US9884868, Example 138'

SMILES NC(=O)c1cnc2ccc(nn12)-c1c(ncn1CCO)-c1ccc(F)c(Cl)c1

InChI Key InChIKey=GZUQQNFNGSZHRU-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 282933   

TargetTGF-beta receptor type-1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM282933(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-...)
Affinity DataIC50: 0.700nMpH: 7.4 T: 2°CAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM282933(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-...)
Affinity DataIC50: 5.98E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1 [T204D](Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM282933(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-...)
Affinity DataIC50: 0.700nMAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM282933(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-...)
Affinity DataIC50: 5.98E+3nMAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM282933(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-...)
Affinity DataIC50: 0.700nMAssay Description:Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM282933(6-(4-(3-chloro-4-fluorophenyl)-1-(2-hydroyxethyl)-...)
Affinity DataIC50: 5.98E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2022
Entry Details
Go to US Patent